BIOA: BioAge Labs Inc. Common Stock Stocks News on January 19, 2025

BIOA

Zacks

17 days ago

BioAge Labs, Inc. (BIOA) Loses -67.99% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

BIOA

Insider Monkey

23 days ago

BioAge Labs, Inc. (BIOA): A Bull Case Theory

BIOA

Pharmaceutical Technology

a month ago

BioAge and Novartis seek drug targets for ageing-related diseases

BIOA

MT Newswires

a month ago

BioAge Labs Says it is Partnering With Novartis to Identify Drug Targets to Treat Age-Related Diseases

BIOA

GlobeNewswire

a month ago

BioAge Labs Announces Multi-Year Collaboration with Novartis to Discover Novel Targets for Therapies that Address Age-Related Diseases and Conditions

3 closely watched drugs that failed in the clinic

BIOA

Pharma Voice

a month ago

3 closely watched drugs that failed in the clinic

BIOA

Clinical Trials Arena

a month ago

BioAge halts ongoing Phase II trial of obesity drug due to liver concerns

BIOA

MT Newswires

a month ago

Top Premarket Decliners

BIOA

Benzinga

a month ago

Just Two Months After IPO, BioAge Labs Stops Eli Lilly-Collaborated Obesity Trial On Safety Concerns

BIOA

MT Newswires

a month ago

Jefferies Downgrades BioAge Labs to Hold From Buy, Adjusts Price Target to $7 From $42

BIOA

MT Newswires

a month ago

Citigroup Downgrades BioAge Labs to Neutral From Buy, Adjusts Price Target to $7 From $45

BIOA

BioPharma Dive

a month ago

BioAge shares tumble after decision to halt obesity drug study

BIOA

MT Newswires

a month ago

BioAge Labs Terminates Phase 2 Trial of Obesity Drug Candidate

BIOA

GlobeNewswire

a month ago

BioAge Labs Announces Discontinuation of STRIDES Phase 2 Clinical Trial Evaluating Azelaprag in Combination with Tirzepatide for the Treatment of Obesity

BIOA

GlobeNewswire

a month ago

BioAge Labs to Present at Goldman Sachs “Year-Ahead” Catalyst Clinic

BIOA

Insider Monkey

a month ago

Why BioAge Labs (BIOA) is the Best All-Time Low Stock to Buy Right Now?

BIOA

GlobeNewswire

2 months ago

BioAge Labs to Present at Upcoming Investor Conferences

BIOA

TipRanks

2 months ago

BioAge Labs Reports Strong Q3 2024 Achievements

BIOA

GlobeNewswire

2 months ago

BioAge Labs Reports Third Quarter 2024 Financial Results and Provides Business Updates

BIOA

GlobeNewswire

2 months ago

BioAge Labs to Present Preclinical Data for APJ Agonist Azelaprag at ObesityWeek 2024

BIOA

GlobeNewswire

3 months ago

BioAge Labs to Present at Jefferies London Healthcare Conference

BIOA

Investing.com

3 months ago

Wall Street analysts initiate coverage of BioAge Labs

Prediction: These 2 Stocks Could Soar in 2025

BIOA

Motley Fool

3 months ago

Prediction: These 2 Stocks Could Soar in 2025

Interested in Weight Loss Stocks Besides Novo Nordisk and Eli Lilly? You Might Want To Check Out This New IPO Stock

BIOA

Motley Fool

3 months ago

Interested in Weight Loss Stocks Besides Novo Nordisk and Eli Lilly? You Might Want To Check Out This New IPO Stock

BIOA

GuruFocus.com

3 months ago

RA Capital Management, L.P. Acquires New Stake in Bioage Labs Inc

BIOA

Motley Fool

3 months ago

3 Reasons to Buy BioAge Labs Stock Hand Over Fist in October

This IPO Biotech Stock Could Be the Next Eli Lilly

BIOA

Motley Fool

4 months ago

This IPO Biotech Stock Could Be the Next Eli Lilly

BIOA

MT Newswires

4 months ago

BioAge Labs Raises $238.3 Million From IPO, Private Placement

BIOA

GlobeNewswire

4 months ago

BioAge Labs Announces Closing of Initial Public Offering, Full Exercise of Underwriters’ Option to Purchase Additional Shares and Closing of the Concurrent Private Placement

Latest BioAge Labs Inc. Common Stock (BIOA) News on January 19, 2025

BioAge Labs, Inc. (BIOA) Loses -67.99% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

BioAge Labs, Inc. (BIOA): A Bull Case Theory

BioAge and Novartis seek drug targets for ageing-related diseases

BioAge Labs Says it is Partnering With Novartis to Identify Drug Targets to Treat Age-Related Diseases

BioAge Labs Announces Multi-Year Collaboration with Novartis to Discover Novel Targets for Therapies that Address Age-Related Diseases and Conditions

3 closely watched drugs that failed in the clinic

BioAge halts ongoing Phase II trial of obesity drug due to liver concerns

Top Premarket Decliners

Just Two Months After IPO, BioAge Labs Stops Eli Lilly-Collaborated Obesity Trial On Safety Concerns

Jefferies Downgrades BioAge Labs to Hold From Buy, Adjusts Price Target to $7 From $42

Citigroup Downgrades BioAge Labs to Neutral From Buy, Adjusts Price Target to $7 From $45

BioAge shares tumble after decision to halt obesity drug study

BioAge Labs Terminates Phase 2 Trial of Obesity Drug Candidate

BioAge Labs Announces Discontinuation of STRIDES Phase 2 Clinical Trial Evaluating Azelaprag in Combination with Tirzepatide for the Treatment of Obesity

BioAge Labs to Present at Goldman Sachs “Year-Ahead” Catalyst Clinic

Why BioAge Labs (BIOA) is the Best All-Time Low Stock to Buy Right Now?

BioAge Labs to Present at Upcoming Investor Conferences

BioAge Labs Reports Strong Q3 2024 Achievements

BioAge Labs Reports Third Quarter 2024 Financial Results and Provides Business Updates

BioAge Labs to Present Preclinical Data for APJ Agonist Azelaprag at ObesityWeek 2024

BioAge Labs to Present at Jefferies London Healthcare Conference

Wall Street analysts initiate coverage of BioAge Labs

Prediction: These 2 Stocks Could Soar in 2025

Interested in Weight Loss Stocks Besides Novo Nordisk and Eli Lilly? You Might Want To Check Out This New IPO Stock

RA Capital Management, L.P. Acquires New Stake in Bioage Labs Inc

3 Reasons to Buy BioAge Labs Stock Hand Over Fist in October

This IPO Biotech Stock Could Be the Next Eli Lilly

BioAge Labs Raises $238.3 Million From IPO, Private Placement

BioAge Labs Announces Closing of Initial Public Offering, Full Exercise of Underwriters’ Option to Purchase Additional Shares and Closing of the Concurrent Private Placement

Share on Social Networks: